McKesson Corporation
MCK · NYSE
MCK · NYSE
McKesson operates in the middle of healthcare, distributing enormous volumes of pharmaceuticals and serving specialty medical practices. Its business includes pharmaceutical distribution and specialty healthcare activities, with specialty pharmaceuticals and oncology identified as important growth areas. Customers include medical practices and other healthcare participants that need medicines moved through the supply chain. McKesson generated $403.4 billion of revenue and $4.8 billion of net income in fiscal 2026, compared with $359.1 billion and $3.3 billion, respectively, in fiscal 2025. The figures show very large scale but relatively modest net margins characteristic of distribution.
The stock fell 6.64%, from $889.50 to $830.43, over the supplied week. It was nearly unchanged on July 29 before declining on July 30 and July 31, dropping another 3.4% on August 3, then recovering modestly on August 4. No company-specific earnings release occurred during the period; McKesson’s Q1 fiscal 2027 conference call was scheduled for August 5. Pre-earnings concerns highlighted in the supplied coverage included tariffs, funding pressure, pricing challenges and possible GLP-1 drug pricing pressure, despite specialty-pharmaceutical demand, oncology growth and AI-led efficiency opportunities. The evidence does not identify a broader market catalyst, so the move appears primarily associated with pre-earnings positioning and concerns already affecting sentiment toward drug distributors.
